Irinotecan Liposome Injection combined with 5-FU/LV
Sponsors
CSPC Ouyi Pharmaceutical Co., Ltd., Shenzhen Majory Biotechnology Co., Ltd.
Conditions
Advanced Pancreatic CancerPancreatic Ductal Adenocarcinoma (PDAC)
Phase 1
Bioequivalence Study of Irinotecan Liposome Injection in Chinese Advanced Pancreatic Cancer.
NCT04482257
Start: 2020-07-07End: 2021-03-31Target: 48Updated: 2020-07-22
A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy
RecruitingNCT07235202
Start: 2025-12-24End: 2028-12-22Target: 45Updated: 2025-12-31